Wall Street Trader schreef op 22 december 2019 10:39:
[...]
"Pasha Sarraf, M.D., Ph.D., Dylan Dupuis, Ph.D., Mike Kratky, CFA"GLPG will be advancing 3 TOLEDO molecules in the clinic in 2020. The goal of developing multiple TOLEDO molecules is to leverage targeting of different combinations of TOL1, 2, and 3. Targeting different combinations will produce different safety/efficacy profiles that
may provide distinct advantages in particular indications.
1st generation TOLEDO molecule GLPG3312 is a pan-TOL inhibitor entering a small Phase 2 proof of concept (PoC) trial in IBD expected to readout in 2H20. In follow-up discussions,
management stated that GLPG3312 demonstrated the best results they had ever seen across all preclinical IBD models. GLPG3970 is a 2nd generation TOLEDO molecule that selectively inhibits TOL2 and TOL3 while sparing TOL1.
Multiple Phase 2 Proof of Concept (PoC) trials are planned for GLPG3970 in 2020 that are expected to begin reading out in 2H20.
GLPG4399 is a selective TOL3 inhibitor that will begin Phase 1 PK/safety studies in 2020. This is the
only TOLEDO molecule thus far that has not demonstrated efficacy in IBD, presumably due to its lack of influence on IL-10 expression. Instead,
GLPG will initially develop this molecule in RA.
GLPG intends to reveal 4th and 5th generation TOLEDO molecules in 2020.GLPG envisions development of the TOLEDO molecules taking place in three waves. The first wave will include initial Phase 1 dosing studies followed by small PoC trials.
Wave 2 will include dose-finding and larger PoC studies that we expect will trigger opt-in decisions from GILD.
Wave 3 will investigate TOLEDO in indications outside of inflammation. GLPG is currently working to better understand the science surrounding these molecules and their implications outside of inflammation.
Each TOLEDO molecule will be considered a separate asset, with each having its own $150M opt-in fee where Gilead opts-in. Galapagos will be eligible to receive 20-24% tiered royalties on all future ex-European sales, with Galapagos retaining full commercial rights in Europe.